Epibatidine and pain

British Journal of Anaesthesia

Volumn 81, Issue 1, 1998, Pages 69-76

  Traynor, John R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Analgesia; Epibatidine; Nicotinic; Nociception; Pain, experimental; Receptors

Indexed keywords

2 FLUORO 3 (AZETIDINYLMETHOXY)PYRIDINE F 18; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; CALCIUM ION; EPIBATIDINE; EPIBOXIDINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ANTINOCICEPTION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

EID: 0031851371     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/81.1.69     Document Type: Review

References (78)

1. Aceto MD, Awaya H, Martin BR, May EL. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. British Journal of Pharmacology 1983; 79: 869-876.
2. Alkondon M, Albuqueque EX. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. I. Pharmacological and functional evidence for distinct structural subtypes. Journal of Pharmacology and Experimental Therapeutics 1993; 265: 1455-1473.
3. Alkondon M, Reinhardt S, Lobron C, Hermsen B, Maelicke A, Albuquerque E. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist elicited whole cell currents and identification of receptor subunits by in situ hybridization. Journal of Pharmacology and Experimental Therapeutics 1994; 271: 494-506.
4. Arqueros L, Naquira D, Zuinino E. Nicotine-induced release of catecholamines from rat hippocampus and striatum. Biochemical Pharmacology 1978; 27: 2667-2674.
5. Asghar K, Roth LJ. Entry and distribution of hexamethonium in the central nervous system. Biochemical Pharmacology 1971; 20: 2787-3795.
6. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Molecular Pharmacology 1994; 45: 563-569.
7. Badio B, Garraffo HM, Plummer CV, Padgett WL, Daly JW. Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine. European Journal of Pharmacology 1997; 321: 189-194.
8. Bannon AW, Gunther KL, Decker MW, Arneric SP. The influence of BAY K 8644 on (± )-epibatidine-induced analgesia. Brain Research 1995; 678: 244-250.
9. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD3 Williams M, Arneric SP. Broad-spectrum non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998; 279: 77-81.
10. Bannon AW, Gü nther KL, Decker MW. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (± )-epibatidine. Pharmacology, Biochemistry and Behavior 1995; 51 : 693-698.
11. Bonhaus DW, Bley KR, Broka CA, Fontana DJ, Leung E, Lewis R, Shiek A, Wong EHF. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. Journal of Pharmacology and Experimental Therapeutics 1995; 272: 1199-1203.
12. Bradley D. Frog venom cocktail yields a one-handed painkiller. Science 1993; 261: 1117.
13. Brioni JD, Decker MW, Sullivan JP, Arneric SP. The pharmacology of (-)- nicotine and novel cholinergic channel modulators. Advances in Pharmacology 1997; 37: 153-213.
14. Broka C. Total synthesis of epibatidine. Tetrahedron Letters 1993; 34: 3251-3254.
15. Christensen MK, Smith DF. Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal rats. Journal of Neural Transmission 1990; 80: 189-194.
16. 125I]bungarotoxin. Journal of Neuroscience 1985; 5: 1307-1315.
17. Colquhoun LM, Patrick JW. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Advances in Pharmacology 1997; 39 : 191-219.
18. Damaj MI, Welch SP, Martin BR. Involvement of calcium and L-type channels in nicotine-induced antinociception. Journal of Pharmacology and Experimental Therapeutics 1993; 266: 1330-1338.
19. Damaj MI, Martin BR. Is the dopamine system involved in the central effects of nicotine in mice? Psychopharmacology 1993; 111: 106-108.
20. Damaj AH, Creasy KR, Grove AD, Rosecrans JA, Martin BR. Pharmacological effects of epibatidine optical enantiomers. Brain Research 1994; 664: 34-40.
21. Damaj MI, Martin BR. Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. European Journal of Pharmacology 1996; 300: 51-57.
22. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. Journal of Pharmacology and Experimental Therapeutics 1997; 282: 445-451.
23. Decker MW, Brioni JD, Bannon AW, Arneric SP. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapies. Life Sciences 1995; 56: 545-570.
24. Domino EF. Behavioral, electrophysiological, endocrine and skeletal muscle actions of nicotine and tobacco smoking. In: Redmond A, Izard C, eds. Electrophysiological Effects of Nicotine. Amsterdam: Elsevier/North Holland Biomedical Press, 1979; 133-146.
25. Fertig JB, Pomerleau OF, Sanders B. Nicotine-produced antinociception in minimally deprived smokers and ex-smokers. Addictive Behaviors 1986; 11: 239-248.
26. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annual Review of Neuro science 1991; 14: 219-245.
27. Fisher M, Hangfu D, Shen T, Guynet P. Epibatidine, an alkaloid from the poison frog Epipedobates tricolor, is a powerful ganglionic depolarising agent. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 702-707.
28. Fletcher SR, Baker R, Chambers MS, Hobbs SC, Mitchell PJ. The synthesis of (+) and (-)-epibatidine. Journal of the Chemical Society Chemical Communications 1993; 15: 1216-1218.
29. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of nicotinic cholinergic receptor in rat brain is composed of α 4 and β 2 subunits and is up-regulated by chronic nicotine treatment. Molecular Pharmacology 1992; 41: 31-37.
30. Galzi JL, Bertrand S, Corringer PJ, Changeux JP, Bertrand D. Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor. EMBO Journal 1996; 15: 5824-5832.
31. Gerzanich V, Peng X, Wang F, Wells G, Anand R, Fletcher S, Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Molecular Pharmacology 1995; 48: 774-782.
32. Gopalakrishnan M, Monteggia LM, Anderson DJ, Arneric SP, Sullivan JP. Stable expression, pharmacologic properties and regulation of the human nicotinic acetylcholinc α 4β 2 receptor. Journal of Pharmacology and Experimental Therapeutics 1996; 276: 289-297.
33. Harvey SC, Maddox FN, Luetje CW. Multiple determinants of dihydro-β -erythroidine sensitivity on rat neuronal nicotinic receptor α -subunits. Journal of Neurochemistry 1996; 67: 1953-1959.
34. Horti A, Scheffel U, Stathis M, Finley P, Ravert HT, London ED, Dannals RF. Fluorine-18-FPH for PET imaging of nicotinic acetylcholine receptors. Journal of Nuclear Medicine 1997; 38: 1260-1265.
35. 3H] epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Molecular Pharmacology 1995; 48: 280-287.
36. Huang DF, Shen TY. A versatile total synthesis of epibatidine and analogs. Tetrahedron Letters 1993; 34: 4477-4480.
37. Iwamoto ET, Marion L. Adrenergic, serotenergic and cholinergic components of nicotine anti-nociception in rats. Journal of Pharmacology and Experimental Therapeutics 1993; 265: 777-789.
38. Kammerling SG, Wettstein JG, Sloan JW, Su TP, Martin WR. Interaction between nicotine and endogenous opioid mechanisms in the unanesthetized dog. Pharmacology, Biochemistry and Behavior 1982; 17: 733-740.
39. Khan IM, Yaksh TL, Taylor P. Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: studies with nicotine and cytisine. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 159-166.
40. Khan IM, Yaksh TL, Taylor P. Epibatidine binding sites and activity in the spinal cord. Brain Research 1997; 753: 269-282.
41. Lindstrom JM. Nicotinic acetylcholine receptors. In: North RA, ed. Handbook of Receptors and Channels. Boca Raton, Florida: CRC Press, 1994; 153-175.
42. 3H]epibatidine. European Journal of Pharmacology 1995; 278: R1-R2.
43. Lukas RJ. Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal cell line. Journal of Pharmacology and Experimental Therapeutics 1993; 265: 294-302.
44. Marks MJ, Stitzel JA, Romm E, Wehner JM, Collins AC. Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine and α -bungarotoxin. Molecular Pharmacology 1986; 30: 427-436.
45. Martin TJ, Suchocki JS, May EL, Martin BR. Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine. Journal of Pharmacology and Experimental Therapeutics 1990; 254: 45-51.
46. Mattila MJ, Ahtee L, Saarnivaara L. The analgesic and sedative effects of nicotine in white mice, rabbits and golden hamsters. Annales Medicinae Experimental et Biologiae Fenniae 1968; 46: 78-84.
47. McGhee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annual Review of Physiology 1995; 57: 521-546.
48. Milgrom-Friedman J, Penman R, Meares R. A preliminary study on pain perception and tobacco smoking. Clinical and Experimental Pharmacology and Physiology 1983; 10: 161-169.
49. Miller L. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clinical Pharmacokinetics 1989; 17: 90-108.
50. Mulle C, Choquet D, Korn H, Changeux JP. Calcium influx through nicotinic receptor in rat central neurons: its relevance to cellular regulation. Neuron 1992; 8: 135-143.
51. Mulle C, Lena C, Changeux JP. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron 1992; 8: 937-945.
52. Musachio JL, Horti A, London ED, Dannais RF. Synthesis of a radioiodinated analog of epibatidine: (+)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo-[2.2.1]heptane for the in vitro and in vivo studies of nicotinic acetylcholine receptors. Journal of Radiolabeled Compounds and Radiopharmaceuticals 1997; 39: 39-48.
53. 3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. Journal of Pharmacology and Experimental Therapeutics 1995; 275: 1030-1034.
54. Pomerleau O. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacology Bulletin 1986; 22: 865-869.
55. Puttfarken PS, Manelli AM, Arneric SP, Donnelly-Roberts DL. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: studies with F11 cells. Journal of Neurochemistry 1997; 69: 930-938.
56. Qian C, Li T, Shen TY, Ubertine-Garahan L, Eckman J, Bifru T, Ip S. Epibatidine is a nicotinic analgesic. European Journal of Pharmacology 1993; 250: R13-R14.
57. Rao TS, Correa LD, Reid RT, LLoyd GK. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (nAChR) ligands in the rat tail-flick assay. Neuropharmacology 1996; 35: 393-405.
58. Rupniak NMJ, Patel S, Marwood R, Webb J, Traynor JR, Elliott J, Freedman SB, Fletcher SR, Hill RG. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. British Journal of Pharmacology 1994; 113: 1487-1493.
59. Sacaan AI, Menzaghi F, Dunlop JL, Correa LD, Whelan KT, Lloyd GK. Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats. Journal of Pharmacology and Experimental Therapeutics 1995; 276: 509-515.
60. Sahley TL, Berntson GG. Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacology 1979; 65: 279-283.
61. 125I]neuronal bungarotoxin. Journal of Neuroscience 1991; 11: 287-297.
62. Smith TW, Traynor JR. Opiates and potent analgesics. In: Feldman SA, Paton W, Scurr C, eds. Mechanisms of Drugs in Anaesthesia. London: Edward Arnold, 1993; 399-412.
63. Spande TF, Garraffo HM, Edwards MW,Yeh HJC, Pannell L, Daly JW. Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran frog. Journal of the American Chemical Society 1992; 114: 3475-3478.
64. Spence A. Report of the working party on pain after surgery. London: The Royal College of Surgeons of England and College of Anaesthetists, 1990.
65. Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, Kang CH, Adams P, Piattoni-Kaplan M, Buckley MJ, Gopalakrishnan M, Williams M, Arneric SP. (± )-epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics 1994; 271: 624-631.
66. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger A-M, Garvey DS, Wasicak JT, Holladay MW, Williams M, Arneric SP. A-85380 [3-(2(S)-azetidinylmethoxy)pyridine]: in vitro pharmacological properties of a novel, high affinity α 4β 2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996; 35: 725-734.
67. Tripathi HL, Martin BR, Aceto MD. Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. Journal of Pharmacology and Experimental Therapeutics 1982; 221: 91-96.
68. Vernino S, Amador M, Luetje CW, Patrick J, Dani JA. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron 1992; 8: 127-134.
69. Vernino S, Rogers M, Radcliffe KA, Dani JA. Quantitative measurement of calcium flux through muscle and neuronal nicotinic acetylcholine receptors. Journal of Neuroscience 1994; 14: 5514-5524.
70. Waller D, Schalling D, Levander S, Edman G. Smoking, pain tolerance, and physiological activation. Psychopharmacology 1983; 79: 193-198.
71. Warpman U, Nordberg A. Epibatidine and ABT418 reveal selective losses of α 4β 2 nicotinic receptors in Alzheimer brains. Neuroreport 1995; 6: 2419-2423.
72. Watt AP, Verrier HM, O'Connor D. Resolution of synthetic (+) and (-)-epibatidine by chiral high performance liquid chromatography and identification of the natural enantiomer. Journal of Liquid Chromatography 1994; 17: 1257-1264.
73. Westera G, Part JT, Jankowski K. Epibatidine-derivatives: ligands for the neuronal nicotinic acetylcholine receptor. In: Annual Report Paul Scherrer Institute. Villigen, Switzerland: Paul Scherrer Institute, 1996. (http: //www.psi.ch/www. irp_hn/clinic.html)
74. Westfall TC, Grant H, Perry H. Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors. General Pharmacolology 1983; 14: 321-325.
75. Whiting P, Schoepfer R, Lindstrom J, Priestley T. Structural and pharmacological characterization of the major brain nicotinic acetylcholine receptor subtype stably expresses in mouse fibroblasts. Molecular Pharmacology, 1992, 40, 463-472.
76. Wonnocott S, Irons J, Rapier C, Thorne B, Lunt GG. Presynaptic modulation of neurotransmitter release by nicotinic receptors. In: Nordberg A, Fuxe K, Holmstedt B, Sundwall A, eds. Progress in Brain Research. Amsterdam: Elsevier, 1990; 157-163.
77. 3H]nicotine binding by enantiomers of nicotine, nornicotine and anatoxinA in membranes and solubilibised preparations of different brain regions of rat. Naunyn-Schmiedeberg's Archives of Pharmacology 1993; 348: 28-34.
78. Zoli M, LeNovere N, Hill JA, Changeux JP. Developmental regulation of nicotininc ACh receptor subunit mRNA's in the rat central and peripheral nervous systems. Journal of Neuroscience 1995; 15: 1912-1939.